WO1993004163A1 - Strain of chlamydia - Google Patents
Strain of chlamydia Download PDFInfo
- Publication number
- WO1993004163A1 WO1993004163A1 PCT/US1992/007103 US9207103W WO9304163A1 WO 1993004163 A1 WO1993004163 A1 WO 1993004163A1 US 9207103 W US9207103 W US 9207103W WO 9304163 A1 WO9304163 A1 WO 9304163A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chlamydia
- strain
- sfpd
- sample
- animal
- Prior art date
Links
- 241000606161 Chlamydia Species 0.000 title claims abstract description 27
- 241000699800 Cricetinae Species 0.000 claims abstract description 65
- 230000002062 proliferating effect Effects 0.000 claims abstract description 41
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 208000009326 ileitis Diseases 0.000 claims abstract description 24
- 241001495184 Chlamydia sp. Species 0.000 claims description 56
- 239000000523 sample Substances 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 46
- 241001465754 Metazoa Species 0.000 claims description 32
- 210000000936 intestine Anatomy 0.000 claims description 23
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 17
- 210000002919 epithelial cell Anatomy 0.000 claims description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 15
- 210000002966 serum Anatomy 0.000 claims description 14
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 13
- 239000002853 nucleic acid probe Substances 0.000 claims description 13
- 238000009396 hybridization Methods 0.000 claims description 12
- 241000282898 Sus scrofa Species 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 230000000968 intestinal effect Effects 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 6
- 241000282339 Mustela Species 0.000 claims description 5
- 230000002550 fecal effect Effects 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 3
- 102000001974 Hyaluronidases Human genes 0.000 claims description 3
- 229960002773 hyaluronidase Drugs 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 241000700199 Cavia porcellus Species 0.000 claims description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 239000012620 biological material Substances 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 230000001902 propagating effect Effects 0.000 claims 2
- 241000282341 Mustela putorius furo Species 0.000 claims 1
- 102000003992 Peroxidases Human genes 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 42
- 230000003834 intracellular effect Effects 0.000 abstract description 26
- 241000894007 species Species 0.000 abstract description 15
- 241000589876 Campylobacter Species 0.000 abstract description 9
- 241000606153 Chlamydia trachomatis Species 0.000 abstract description 8
- 241001647378 Chlamydia psittaci Species 0.000 abstract description 4
- 238000013081 phylogenetic analysis Methods 0.000 abstract description 4
- 229940038705 chlamydia trachomatis Drugs 0.000 abstract description 2
- 238000004113 cell culture Methods 0.000 description 26
- 239000000706 filtrate Substances 0.000 description 19
- 230000001580 bacterial effect Effects 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 238000005119 centrifugation Methods 0.000 description 12
- 208000004232 Enteritis Diseases 0.000 description 11
- 239000012981 Hank's balanced salt solution Substances 0.000 description 10
- 210000003754 fetus Anatomy 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 239000003298 DNA probe Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 210000003405 ileum Anatomy 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 238000000386 microscopy Methods 0.000 description 6
- 238000012809 post-inoculation Methods 0.000 description 6
- 108020004418 ribosomal RNA Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000589875 Campylobacter jejuni Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 238000013019 agitation Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 description 5
- 230000008719 thickening Effects 0.000 description 5
- 241000324543 Chlamydia psittaci 6BC Species 0.000 description 4
- 241000590002 Helicobacter pylori Species 0.000 description 4
- 238000011887 Necropsy Methods 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 241000588767 Proteus vulgaris Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940037467 helicobacter pylori Drugs 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 229940007042 proteus vulgaris Drugs 0.000 description 4
- 238000007790 scraping Methods 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 208000037902 enteropathy Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 206010067993 Mucosal necrosis Diseases 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000008556 epithelial cell proliferation Effects 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 210000000680 phagosome Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- PCDWFBFHIIKIPM-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-2-sulfonic acid Chemical compound C1=CC=C2N(CC)C(S(O)(=O)=O)SC2=C1 PCDWFBFHIIKIPM-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000002310 Achlorhydria Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000589872 Campylobacter hyointestinalis Species 0.000 description 1
- 241000589995 Campylobacter mucosalis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 241000554738 Rusa Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000596212 Vulpes lagopus Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940106721 tagamet Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- hyperplasia is a disease of hamsters
- Bacteria, viral agents, and neoplasia have all been implicated as possible etiologies for the disease.
- oral inoculation of hamsters with pure cultures of C. jejuni has been uniformly unsuccessful in
- Campylobacter hyointestinalis has also been isolated from hamsters, but attempts to reproduce proliferative ileitis by oral inoculation of pure cultures of C.
- Proliferative bowel diseases, or enteropathies characterized by intraepithelial Campylobacter-like bacteria are well-known in swine as well as hamsters, and have also been reported in ferrets, sheep, rats, guinea pigs, dogs, a foal, a blue fox, Holuccan rusa deer, and rabbits.
- Porcine proliferative enteritis is a disease which occurs naturally in swine and has been linked for some time with the intracellular presence of
- Porcine proliferative enteritis occurs in pigs of weaning age or older but is primarily observed in feeder pigs (14 to 15 kg) and in gilts (bred), sows, and boars. The disease is worldwide in distribution, having been reported in the United States, United Kingdom, Sweden, Australia, Denmark, and Taiwan.
- Gross lesions are characterized by thickening of the wall of the ileum primarily, but also of the jejunum, cecum, and colon. There are reticulation of the serosa, hyperemia and edema of the mesentery, and enlarged
- the affected intestinal segment may contain variable amounts of fibrin, necrotic material, and blood in the lumen.
- the underlying mucosa has prominent mucosal folds and a granular appearance and is hyperemic. Occasionally, there are diffuse areas of mucosal necrosis and prominent thickening of the tunica muscularis.
- Campylobacter-like organisms found in conjunction with either hamster or swine enteritis are free within immature epithelial cell cytoplasm, are 2 to 3 ⁇ m. long and 0.2 to 0.3 ⁇ m in diameter, and have a trilaminar, undulating cell wall.
- the organism apparently penetrates immature crypt epithelial cells preferentially, by passing through the microvillous border of these cells.
- multifocal to diffuse degeneration of the superficial epithelium 5 characterized by rounding, vacuolation, and sloughing of epithelial cells.
- the present invention relates to the discovery of a novel intracellular bacterium in hamsters with
- intracellular bacterium has been isolated in purified form and, on the basis of phylogenetic analysis, has been determined to possess 95% similarity to Chlamydia psittaci and 98% similarity to Chlamydia trachomatis.
- proliferative bowel diseases in other species as well are not members of Campylobacter genus at all, but rather appear to be a novel species of Chlamydia.
- This purified and isolated bacterium hereinafter referred to as
- Chlamydia sp. strain SFPD was deposited at the American Type Culture Collection (ATCC), Rockville, Maryland, on August 21, 1991, and accorded Accession No. M83313.
- transmissible proliferative ileitis includes transmissible ileal
- This invention also relates to methods to identify infected swine, hamsters, ferrets, rabbits, etc. ,
- Either monoclonal or polyclonal antibodies can be utilized for such diagnostic purposes, in both feces and tissues, and can be directed against either the genus
- DNA probes useful for clinical diagnosis of the aforementioned proliferative bowel diseases and characterized by a high degree of specificity and
- selectivity for the organism of the present invention can be advantageously employed now that the identity and phylogenetic structure of the organism have been deduced.
- This invention further relates to methods of
- the intracellular organism of the present invention was isolated from ileal epithelial cells of a hamster with transmissible proliferative ileitis (TPI). The procedure followed is set forth in considerable detail in Example 1, but will be briefly summarized here.
- the ileal epithelial cells were isolated by hyaluronidase digestion and gradient centrifugation.
- the ileal epithelial cells were isolated by hyaluronidase digestion and gradient centrifugation. The ileal
- epithelial cell suspension was then lysed with 0.2% Triton X-100 and the intracellular organism collected by centrifugation following filtration of the lysed
- the organism was isolated following inoculation of 70-80% confluent Intestine 407 human embryonic intestinal cell (ATCC CCL 6) monolayers. Growth of the organism was first detected at day 8 post-inoculation and was
- Example 1 typical lesions of proliferative ileitis were successfully reproduced in hamsters inoculated per os with the infected cell-free filtrate and 0.65- ⁇ m-pore-size filtrate, while littermates given the uninfected control cellfree filtrate and
- the organism then was reisolated from one of the 0.65- ⁇ m-pore-size filtrate-inoculated hamsters which developed proliferative ileitis. The organism was not recovered from hamsters inoculated with uninfected control cell filtrate or the 0.2- ⁇ m-pore-size filtrate.
- the novel strain of Chlamydia appears to fulfill the criteria to be considered an etiologic agent of transmissible proliferative ileitis.
- Chlamydia are typically resistant would be advantageous. Utilization of vancomycin, amphotericin B, and members of the aminoglycoside group of antibiotics (gentamicin, neomycin, streptomycin, etc.) in cell culture isolation effectively suppresses contaminating bacterial organisms while permitting Chlamydia growth.
- vancomycin, amphotericin B, and members of the aminoglycoside group of antibiotics gentamicin, neomycin, streptomycin, etc.
- Chlamydia had never been implicated.
- respected researchers in the field had gone so far as to publish journal articles dismissing Chlamydia as a potential causative agent
- Chlamydia as an agent is believed to stem, in part, from the atypical behavior exhibited by the novel strain of
- Chlamydia described herein.
- trachomatis and C. psittaci are known to have an affinity for epithelial cells of mucous membranes, and attachment and penetration appear to involve a heat-labile surface component on the infectious elementary bodies and a trypsin-sensitive receptor on the host cells.
- 16S rRNA was isolated and sequenced as described in detail in Example 2. Briefly, for 16S RNA sequencing, the novel bacterium was isolated from infected cell culture and media supernate by centrifugation at 800 x g to remove cell debris, followed by isolation of the organism at
- Chlamydia as discussed in Example 2. Based on this analysis, the organism isolated in conjunction with the present invention is believed to be a new strain, and possibly a new species, of Chlamydia.
- polyclonal antibodies, reactive with Chlamydia sp. strain SFPD can be used in diagnostic immunoassys, such as ELISAs, RIAs, to detect the presence of Chlamydia sp. strain SFPD in biological samples which include fecal material and tissue.
- monoclonal antibodies can be generated using the Chlamydia sp. strain SFPD, isolated by the methods described herein, and standard techniques well known to those skilled in the art. These monoclonal antibodies can be used in diagnostic assays as described above.
- the isolated Chlamydia sp. strain SFPD can be used as an antigen in an immunoassay, such as the ELISA described in Example 1, to detect antibodies to Chlamydia sp. strain SFPD found in the serum of animals infected with the bacterium.
- an immunoassay such as the ELISA described in Example 1, to detect antibodies to Chlamydia sp. strain SFPD found in the serum of animals infected with the bacterium.
- Nucleic acid probes are a sensitive and rapid
- pathogens particularly in the case of fastidious or noncultivatable organisms.
- These probes can be either DNA or RNA.
- DNA probes for example, are now in common usage and can be custom-designed in terms of their sizes and specificities for a variety of prospective applications. The sizes of these probes can range from entire plasmids (kilobases in size) down to simple 10- to 15-base
- DNA probes can be tailored to bind to other DNA, ribosomal RNA (rRNA), or messenger RNA (mRNA).
- rRNA ribosomal RNA
- mRNA messenger RNA
- a given probe will bind to specific nucleotide sequences.
- a radioactive, enzymatic, or organic label bound to the probe allows it to be detected.
- DNA probes specific for rRNA sequences have been used successfully in the detection of various pathogens, and various diagnostic kits based on DNA probes are now available for use in clinical labs. The presence of
- Chlamydia sp. strain SFPD in biological samples can be detected using these nucleic acid probes.
- a sample of fecal material from an animal can be hybridized to a DNA probe which is complementary to all, or a
- strain SFPD have been developed as described in detail in Example 3.
- antibodies reactive with Chlamydia sp. strain SFPD can be used to transfer passive immunity to animals susceptible to the bacterium.
- These antibodies either polyclonal or monoclonal, can be formulated for therapeutic use as a pharmaceutical composition comprising appropriate carriers, excipients, and other
- the antibody preparation is formulated as a sterile, non-pyrogenic composition for parenteral administration.
- any pharmaceutically acceptable route and method of administration of antibody for passive transfer of immunity can be used, such as those described in a standard reference text in this field (e.g., Remington's Pharmaceutical Sciences).
- the isolated and purified bacterium Chlamydia sp. strain SFPD can itself be used in a vaccine formulation to be administered to susceptible animals.
- the Chlamydia sp. strain SFPD can be attenuated so that, although the bacterium remains infectious so that it retains its ability to elicit an immune response in the animal, the attenuated bacterium does not cause significant disease in the host animal.
- the administration of the vaccine formulation induces the host animal to produce antibodies reactive against subsequent challenge with Chlamydia sp. strain SFPD, thereby neutralizing the infecting bacterium and preventing significant disease.
- Attenuation can be achieved by multiple passaging of the organism and selecting for a weakened strain.
- Attenuation can also be achieved by mutation of the bacterium using techniques known to those skilled in the art.
- the vaccine formulation can be comprised of killed, not just attenuated, Chlamydia sp. strain SFPD. Killing can be achieved by heat treatment or lethal doses of chemicals, such as formalin. In either case, the bacterium comprising the vaccine formulation is capable of eliciting an immune response in the host animal without significant disease.
- the vaccine will be formulated for therapeutic use as a pharmaceutical composition comprising appropriate carriers, excipients, and other pharmaceutically
- the vaccine formulation may also contain additional materials, such as adjuvants, to increase the immunogenicity of the vaccine. Serum titers of antibodies elicited in response to
- immunization with these vaccine formulations can be determined by use of the diagnostic assays described above.
- EXAMPLE I Isolation of an intracellular bacterium from hamsters with proliferative ileitis and reproduction of the disease with a pure culture
- the aseptically removed ilea of three hamsters with experimentally induced proliferative ileitis provided the source material.
- the ilea were cut into 2.5-cm sections, opened longitudinally, and repeatedly washed with Hank's balanced salt solution (HBSS) without Ca 2 + or Mg 2 + and 1 mM EDTA (HBSS-EDTA) to remove the intestinal contents.
- HBSS-EDTA Hank's balanced salt solution
- the mucus was removed by incubating the ileal sections in 20% (wt/vol) N-acetyl-cysteine (Sigma Chemical Co., St. Louis, Mo.) for 45 min at 37°C with agitation.
- the supernatant was decanted, and the sections were washed twice in HBSS-EDTA and then three times in HBSS. The sections were then transferred to 20 ml of hyaluronidase (1 mg/ml) in HBSS with 5% (wt/vol) bovine serum albumin (BSA) and incubated at 37oC for 2 hr with agitation to free the epithelial cells. The resulting solutions were successively filtered through a sterilized glass
- the crude cell suspensions were centrifuged (400 x g for 10 min) and resuspended in HBSS twice. Following a final centrifugation, the cell pellets were resuspended in 50 ml of Leibovitz L-15 media (Sigma) with 10% fetal calf serum, 100 ⁇ g of gentamicin sulfate (Sigma) per ml, and 2/5 ⁇ g of amphotericin B (Sigma) per ml and incubated overnight at 4°C with agitation.
- the cells were separated by centrifugation (400 x g for 10 min) and washed three times in HBSS-EDTA with 5% BSA and resuspended in a minimal volume of HBSS-EDTA with 5% BSA.
- the cell suspensions were then layered onto preformed (15 min at 15,000 x g and at 4°C) 30% Percoll (Pharmacia LKB Biotechnology, Inc., Piscataway, N.J.) gradients in HBSS-EDTA with 5% BSA and centrifuged at 400 x g for 15 min.
- the epithelial cell bands (density 1.035 g/ml) were suspended in HBSS with 5% BSA and washed four times in HBSS with 5% BSA followed by centrifugation (400 x g, 10 min).
- the cell pellets were resuspended in HBSS with 5% BSA and 0.2% Triton X-100 and incubated at 37oC for 30 min for agitation to effect cell lysis.
- the suspensions were then centrifuged (400 x g, 10 min) to remove cell fragments, and the supernatants were filtered through stacked 20- ⁇ m-pore-size nylon (Micron Separations, Inc., Westboro, Mass.) and 0.65-,ym-pore-size nitrocellulose filters
- Intestine 407 human embryonic intestinal cells (ATCC CCL 6) and GPC-16 guinea pig colonic adenocarcinoma cells (ATCC CCL 242) were grown in Dulbecco's modified Eagle's medium with 4,500 mg of glucose per liter, 110 mg of sodium pyruvate per liter, 584 mg of L-glutamine per liter, and 10% fetal calf serum (DME).
- DME fetal calf serum
- HaK Syrian hamster kidney cells were grown in Eagle's minimum essential media with Hank's salts and 10% fetal calf serum.
- Vero African green monkey kidney cells were grown in medium 199
- each cell line was then inoculated with 500 ⁇ m. of each isolated bacterial
- the inoculum for the control group (group A) was prepared from two 75-cm 2 flasks of confluent uninfected Intestine 407 cells. The cells were mechanically separated from the flask by scraping, concussion, and vortexing. Triton X-100 was then added to the cell media suspension to a
- the infected inocula were prepared in a similar manner except that a total of six 75-cm 2 flasks were processed. Following the filtration through a
- the infected inocula were divided into three portions.
- the group B inoculum was processed identically to the group A control inoculum.
- the group C inoculum was filtered through a 0.65- ⁇ m-pore size cellulose filter (Whatman) prior to final centrifugation, and the group D inoculum was similarly filtered through a 0.2- ⁇ m-pore-size cellulose filter (Whatman) prior to final centrifugation. All inocula were held at 4°C after preparation and were utilized within 3 hr of preparation.
- the weanling hamsters were divided into four groups with a conscious attempt to equalize the sex and weight distribution among the groups.
- Each hamster was given 7.5 mg of cimetidine (Tagamet; SK&F Lab Co., Cidra, Puerto Rico) intraperitoneally 30 min prior to inoculation to induce temporary achlorhydria.
- cimetidine Tagamet; SK&F Lab Co., Cidra, Puerto Rico
- dexamethasone Azium; Schering Corp., Kenilworth, N.J.
- Control group A hamsters (5 male and 3 female) were inoculated with 1 ml of a cell-free filtrate from
- Group B hamsters (5 male and 3 female) were inoculated with 1 ml of a cell-free filtrate from infected Intestine 407 cells.
- Groups C and D hamsters (4 male and 4 female each) were inoculated with 0.65- ⁇ m- and 0.2- ⁇ m-pore-size filtrates from infected Intestine 407 cells.
- a terminal blood sample of 2 ml was drawn from the right ventricle for serum titer determination by enzyme-linked immunosorbent essay (ELISA), and the ileum was aseptically removed. A small section of the ileum was fixed in McDowell-Trump fixative for light and electron microscopy. The remainder of the ileum was either frozen (-80°C) for later use or further processed for organism reisolation.
- ELISA enzyme-linked immunosorbent essay
- IgG anti-hamster immunoglobulin G
- IgG anti-hamster immunoglobulin G
- ELISA wash per well.
- bound antibody was detected by the addition of 100 ⁇ l of 2,2'-azinobis (3-ethylbenzthiazoline sulfonic acid) substrate (Sigma) for 15 min., and the A 405 was determined with an automated ELISA reader (Titertek Multiscan; Flow Laboratories). All assays were performed in duplicate and were repeated if values differed by greater than 10%.
- the bacterial isolate was purified from Intestine 407 cell culture (passage 15 and 16) for antibody production. Culture supernatant was centrifuged at 400 x g for 10 min to remove cell debris, and the resulting supernatant was filtered through a 0.65- ⁇ m-pore-size cellulose acetate filter (Whatman). The filtrate was then centrifuged
- McFarland standard of 0.5 The organism suspension was then emulsified with an equal volume of Fruend's complete adjuvant (Sigma Chemical Co.).
- Each rabbit was injected with a total of 0.5 ml of the adjuvant-organism mixture divided into 10 sites intradermally on the back.
- a booster injection of 1.0 ml of the organism in Dulbecco's PBS was given subcutaneously at 40 days postinjection, and sera were collected 7 days later.
- the IgG fraction of the rabbit antisera was purified by precipitation with ammonium sulfate (33% final
- IgG fractions were then reprecipitated with ammonium sulfate, isolated by centrifugation, and desalted on a Sephadex G25 column (Pharmacia LKB Biotechnology, Inc.) equilibrated and eluted with PBS.
- Sections were routinely deparaffinized in xylene and rehydrated through decreasingly concentrated ethanol solutions. The sections were then incubated for 1 hr in 0.03% H 2 O 2 in absolute methanol to remove endogenous peroxidase activity.
- the sections were incubated for 1 hr in a blocking solution of 0.2% (vol/vol) Tween 20 and 2.5% (wt/vol) nonfat dry milk in PBS. Following an additional wash, the rabbit anti-organism antibody was applied at a dilution of 1:100 in PBS, and the slides were incubated overnight at 4°C in a humidified chamber. The slides were then washed 4 times in ELISA wash and
- Immunoresearch diluted 1:500 in ELISA wash. The sections were then washed 4 times in ELISA wash, and bound antibody was detected with a commercial peroxidase detection system for immunohistochemistry (HistoMark Black; Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) by following the manufacturer's directions. Controls to ensure
- Intestine 407 cells preimmunization rabbit sera, and organism-adsorbed immune rabbit antibody.
- the organism continued to multiply in the original cell cultures (with additional 2:1 splittings on days 14, 18, and 20) through day 19 postinoculation (Intestine 407) and day 21 postinoculation (GPC-16), when the cultures were contaminated.
- the organism was readily and
- Intestine 407 cell cultures with the supernatant from infected cultures (1 ml of infected supernatant per 25-cm 2 surface area).
- intracellular organisms could be detected by phase microscopy within 72 hr of infection, with the interval between infection and microscopic detection decreasing in later passages.
- Cell culture monolayer viability decreased from 10 days (passage 1) to 6 days by passage 5.
- organisms were detected by phase microscopy at 24 hr post cell culture infection, and monolayer destruction was evident in 4 to 6 days following
- Intracellular bacteria were not detected in the group A (control) inoculated cell culture through 14 days of incubation.
- cytoplasm Macrophages with intracellular bacteria both free in the cytoplasm and in phagosomes were present adjacent to epithelial cells.
- the bacteria were typically slightly curved on longitudinal sections and measured 1.4 to 1.6 ⁇ m in length by 0.25 to 0.38 ⁇ m in width.
- the bacterial cell wall appeared trilaminar and irregular. No flagella were observed.
- infected Intestine 407 cells revealed the presence of bacteria morphologically identical to those seen in the ileal cells of infected hamsters.
- the bacteria in the Intestine 407 cells measured 1.4 to 1.7 ⁇ m in length by 0.26 to 0.34 ⁇ m with a similar trilaminar irregular cell wall.
- a majority of the bacteria in the Intestine 407 cells were free within the cell cytoplasm, although some were membrane bound within vacuoles.
- Serum titers of hamsters from group A ranged from ⁇ 1:100 to 1:1,600, with a median titer of 1:400.
- the serum titers from the group D ranged from ⁇ 1:100 to 1:1,600, with a median titer of 1:400.
- filtrate inocullted ranged from 1:1,600 to >1: 12,800, with a median titer of 1:6,400, while the titers of the group B hamsters ranged from 1:1,600 to >1:12,800, with a median of 1:3,200.
- the serum titers of the group B and group C hamsters were significantly (P ⁇ 0.01,
- Organisms were primarily confined to the apical portions of ileal epithelial cells, with few organisms being present in the lamina intestinal or within the lumen. The distribution of organisms corresponded to the distribution of silver-stained organisms seen on the Warthin-Starry-stained sections from the same hamster. No stained organisms were present within the ileal epithelial cells from any of the 8 group A or 8 group D hamsters.
- Organisms specifically labeled with the polyclonal rabbit anti-organism antibody were also present in the infected Intestine 407 cells. No reactivity was present with uninfected Intestine 407 cells, and reactivity was completely eliminated by adsorption of the rabbit antisera with formalin-fixed organisms.
- EXAMPLE 2 16S rRNA seguencing of the intracellular bacterium isolated in Example 1 and its identification as a novel strain of Chlamydia
- SEQ ID NO:1 The complete sequence (SEQ ID NO:1) is shown in Table 1 In the foregoing sequence, A represents the base adenine, C represents the base cytosine, G represents the base guanine, U represents the base uracil, lower-case letters (a, c, g, etc.) are believed to be their upper-case equivalent although this is not known with certainty, n indicates that the identity of the nucleotide is unknown, and (-) represents a gap in the sequence as aligned with the 16S rRNA sequence of E. coli.
- the numbers above the diagonal represent percent similarity.
- the numbers below the diagonal are percent differences corrected for multiple base changes by the method of Jukes and Cantor (1969).
- Signatures are defined as those segments of the RNA sequence which are unique to any given species or group of phylogenetically-related organisms. Signatures can be found by examination of aligned sequences, noting regions in the desired species or higher phylogenetic group that contain differences at sites conserved in other species. Once such a sequence is found, large numbers of reference sequences are searched (by computer) to verify the
- Chlamydia sp. strain SFPD was compared with over 350 sequences of other bacteria. These signature regions become the target site for DNA probes.
- ABI DNA Synthesizer can be used to synthesize the oligonucleotides which serve as probes.
- oligonucleotides Briefly, the procedure is as follows. 0.5 ug of oligomer (probe) and 200 uCi radiolabeled ATP are combined and dried under vacuum. The dried pellet is dissolved in 0.05 ml of kinase buffer containing 11.5 U of Polynucleotide kinase (Pharmacia). This mixture is incubated at 37°C for 30 min. Ammonium acetate and EDTA are then added to stop the reaction. The reaction mixture (0.5 ml) is gravity loaded onto C-8 Bond-Elute columns (Analytichem. Intern.) and is washed 3X with 1 ml of 50 mM ammonium acetate and then once with 1 ml of 5 mM ammonium acetate.
- Probes can be hybridized with rRNA samples that were used for sequencing reactions. Once these probes have proven to be successful using purified RNA, the probes can be validated using pure cultures of target organisms
- Probes can target 16S rRNA or 16S rRNA regions of the genome.
- the hybridization procedure has been adapted from
- rRNA is denatured in a solution of 6.15 M formaldehyde in 10X SSC (NaCl/Na Citrate buffer) at a temperature of 65°C for 15 min.
- the denatured rRNA is transferred to a prewashed nitrocellulose (NC) filter in a Slot Blot apparatus (Schleicher and Schuell).
- NC nitrocellulose
- Slot Blot apparatus Scholeicher and Schuell. This apparatus is a modified dot blot which allows for rapid, high resolution hybridization of nucleic acids.
- the denatured RNA is baked onto the filter at 80°C for 1h under vacuum. The bake filter is placed in a seal-a-meal plastic bag and hybridization solution containing
- Target sequence (SEQ ID NO: 2)
- Probe sequence (SEQ ID NO: 3)
- Target sequence (SEQ ID NO: 4)
- Probe sequence (SEQ ID NO: 5)
- Target sequence (SEQ ID NO: 6)
- Probe sequence (SEQ ID NO: 7)
- Target sequence (SEQ ID NO: 8)
- Probe sequence (SEQ ID NO: 9) GAAGACGGUUAAUACCCGUUGGAU Chlamydia so. strain SFPD
- Target sequence (SEQ ID NO: 10)
Abstract
The present invention relates to the discovery of a novel intracellular bacterium in hamsters with transmissible proliferative ileitis. This novel intracellular bacterium has been isolated in purified form and, on the basis of phylogenetic analysis, has been determined to possess 95 % similarity to Chlamydia psittaci and 98 % similarity to Chlamydia trachomatis. Thus, it has been discovered that the 'Campylobacter-like organisms' long implicated in proliferative ileitis in hamsters, and likely in proliferative bowel diseases in other species as well, are not members of Campylobacter genus at all, but rather appear to be a novel species of Chlamydia.
Description
STRAIN OF CHLAMYDIA
Description
Background of the Invention
Proliferative ileitis (transmissible ileal
hyperplasia; wet-tail) is a disease of hamsters
characterized by mucosal hyperplasia and by a
pyogranulomaeous inflammation of the distal ileum. The hyperplastic phase of the disease precedes the
inflammatory phase and is characterized by replacement of the normal epithelium with an immature pseudostratified epithelium with a high mitotic index. As the disease progresses, the villi elongate and become leaflike, and the proliferating crypts penetrate into the underlying supporting tissues and Peyer's patches. Secondary
bacterial invasion may result in abscess formation, peritonitis, and ileal rupture. Bacteria, viral agents, and neoplasia have all been implicated as possible etiologies for the disease.
Light microscopic studies have revealed a
gram-negative, slightly curved bacillus within the hyperplastic ileal cells of hamsters with proliferative ileitis. An antibody reactive with this bacillus is produced by hamsters naturally infected with the disease and by those inoculated with homogenized ileal lesions. Ultrastructurally, the organism resembles members of the genus Campylobacter. For this reason, the appellation "Campylobacterlike" has been used in the literature to describe these mysterious bacteria, widely believed to be yet-unidentified members of the genus Campylobacter.
Microbiologic studies have repeatedly associated
Campylobacter jejuni with both naturally occurring and experimentally induced proliferative ileitis in hamsters.
However, oral inoculation of hamsters with pure cultures of C. jejuni has been uniformly unsuccessful in
reproducing the disease. Surgical inoculation of C.
jejuni into the ileum has produced diarrhea and
enterocolitis, but not proliferative lesions.
Campylobacter hyointestinalis has also been isolated from hamsters, but attempts to reproduce proliferative ileitis by oral inoculation of pure cultures of C.
hyointestinalis. as well as Campylobacter mucosalis and Campylobacter coli, have also been unsuccessful.
Proliferative bowel diseases, or enteropathies, characterized by intraepithelial Campylobacter-like bacteria are well-known in swine as well as hamsters, and have also been reported in ferrets, sheep, rats, guinea pigs, dogs, a foal, a blue fox, Holuccan rusa deer, and rabbits.
The etiology and pathogenesis of these proliferative bowel diseases have been poorly understood. Efforts to identify the intracellular bacteria in swine and hamsters have been unsuccessful, and few studies have been
conducted in other species. The consistent location and morphology of the organisms and the similar general characteristics of the lesions in a wide variety of host species have tended to implicate the intracellular bacteria as the etiologic agent(s).
It has been known that the disease could be produced in pigs and hamsters by inoculation with preparations of homogenized intestinal tissue containing intracellular Camoylobacter-like bacteria, and that these preparations were no longer pathogenic after passage through filters which retained bacteria. Successful treatment of enteritis
with antibiotics in rabbits and ferrets also supported the contention that bacteria had at least a contributing etiologic role. However, it has not been possible to obtain cultural isolates of the intraepithelial bacteria or to reproduce the natural disease in gnotobiotic hosts.
Porcine proliferative enteritis (swine proliferative enteritis; porcine necrotic enteritis; porcine hemorrhagic enteropathy; porcine intestinal adenomatosis) is a disease which occurs naturally in swine and has been linked for some time with the intracellular presence of
Campylobacter-like organisms. It is pathologically
comparable to hamster proliferative ileitis (Jonas et al., J. Am. Vet. Med. Assoc., 147:1102-1108), and weanling hamsters have proven to be susceptible to the agent of porcine proliferative enteritis by cross-species
transmission (McOrist et al., Veterinary Microbiology, 15:293-302 (1987)). Porcine proliferative enteritis occurs in pigs of weaning age or older but is primarily observed in feeder pigs (14 to 15 kg) and in gilts (bred), sows, and boars. The disease is worldwide in distribution, having been reported in the United States, United Kingdom, Sweden, Australia, Denmark, and Taiwan.
Gross lesions are characterized by thickening of the wall of the ileum primarily, but also of the jejunum, cecum, and colon. There are reticulation of the serosa, hyperemia and edema of the mesentery, and enlarged
ileocecal lymph nodes. The affected intestinal segment may contain variable amounts of fibrin, necrotic material, and blood in the lumen. The underlying mucosa has prominent mucosal folds and a granular appearance and is hyperemic.
Occasionally, there are diffuse areas of mucosal necrosis and prominent thickening of the tunica muscularis.
Microscopically, there are diffuse proliferation of crypt epithelium, elongation of crypts, and flattening of the villous surface. Variable numbers of macrophages, eosinophils, and neutrophils are present in the lamina propria. There is superficial to full-thickness mucosal necrosis, accompanied by exudation of fibrin, leukocytes, and erythrocytes into the intestinal lumen.
Under electron microscopy, Campylobacter-like organisms (CLO) found in conjunction with either hamster or swine enteritis are free within immature epithelial cell cytoplasm, are 2 to 3 μm. long and 0.2 to 0.3 μm in diameter, and have a trilaminar, undulating cell wall. The organism apparently penetrates immature crypt epithelial cells preferentially, by passing through the microvillous border of these cells. In more severely affected tissues, there is confluent multifocal to diffuse degeneration of the superficial epithelium 5 characterized by rounding, vacuolation, and sloughing of epithelial cells.
While results of immunofluorescence studies have indicated that the organism within the ileal enterocytes differs from known Campylobacter species, most speculation has centered around the proposition that the organism is an as yet uncultured Campylobacter species. (McOrist et al., FEBS Microbiology Letters, 69:189-194 (1990)).
Despite a tremendous amount of research interest and activity in the field, the identity of this mysterious intraepithelial organism has remained shrouded in
speculation, due to an inability to obtain cultural
isolates and/or reproduce the natural disease in
gnotobiotic hosts.
Summary of the Invention
The present invention relates to the discovery of a novel intracellular bacterium in hamsters with
transmissible proliferative ileitis. This novel
intracellular bacterium has been isolated in purified form and, on the basis of phylogenetic analysis, has been determined to possess 95% similarity to Chlamydia psittaci and 98% similarity to Chlamydia trachomatis.
Thus, it has been discovered that the
"Campylobacter-like organisms" long implicated in
proliferative ileitis in hamsters, and likely in
proliferative bowel diseases in other species as well, are not members of Campylobacter genus at all, but rather appear to be a novel species of Chlamydia. This purified and isolated bacterium, hereinafter referred to as
Chlamydia sp. strain SFPD, was deposited at the American Type Culture Collection (ATCC), Rockville, Maryland, on August 21, 1991, and accorded Accession No. M83313.
The present invention also relates to rapid and effective methods for diagnosis of transmissible
proliferative ileitis. As used herein, transmissible proliferative ileitis includes transmissible ileal
hyperplasia in hamsters, porcine proliferative enteritis in swine, porcine necrotic enteritis, porcine hemorrhagic enteropathy, and porcine intestinal adenomatosis, as well as other of the so-called "CLO-associated" proliferative bowel diseases in animals.
This invention also relates to methods to identify infected swine, hamsters, ferrets, rabbits, etc. ,
especially those which are symptomatic and shedding the organism in their feces.
Either monoclonal or polyclonal antibodies can be utilized for such diagnostic purposes, in both feces and tissues, and can be directed against either the genus
Chlamydia or this novel strain of Chlamydia in particular. Alternatively, DNA probes useful for clinical diagnosis of the aforementioned proliferative bowel diseases, and characterized by a high degree of specificity and
selectivity for the organism of the present invention, can be advantageously employed now that the identity and phylogenetic structure of the organism have been deduced.
This invention further relates to methods of
transferring passive immunity to susceptible animals using antibodies that are reactive with Chlamydia sp. strain SFPD, and to vaccines prepared from the novel Chlamydia sp. strain SFPD. Detailed Description of the Invention
The intracellular organism of the present invention was isolated from ileal epithelial cells of a hamster with transmissible proliferative ileitis (TPI). The procedure followed is set forth in considerable detail in Example 1, but will be briefly summarized here.
The ileal epithelial cells were isolated by hyaluronidase digestion and gradient centrifugation. The ileal
epithelial cell suspension was then lysed with 0.2% Triton X-100 and the intracellular organism collected by
centrifugation following filtration of the lysed
suspension through a 0.65 μm filter.
The organism was isolated following inoculation of 70-80% confluent Intestine 407 human embryonic intestinal cell (ATCC CCL 6) monolayers. Growth of the organism was first detected at day 8 post-inoculation and was
maintained in cell culture by repeated passage.
As further described in Example 1, typical lesions of proliferative ileitis were successfully reproduced in hamsters inoculated per os with the infected cell-free filtrate and 0.65-μm-pore-size filtrate, while littermates given the uninfected control cellfree filtrate and
0.2-μm-pore-size filtrate remained free of disease.
The organism then was reisolated from one of the 0.65-μm-pore-size filtrate-inoculated hamsters which developed proliferative ileitis. The organism was not recovered from hamsters inoculated with uninfected control cell filtrate or the 0.2-μm-pore-size filtrate.
Thus, the novel strain of Chlamydia appears to fulfill the criteria to be considered an etiologic agent of transmissible proliferative ileitis. The 0.2μm
pore-size filtrate did not reproduce the disease,
suggesting that the causative organism is larger than a virus. Extensive transmission electron microscopic
examinations also failed to detect any viral particles or other bacteria within the infected cells. The nearly identical ultrastructural morphology of this novel strain of Chlamydia within the infected cells utilized in the examples and infected hamster ileal epithelium supports the role of the bacterium in disease pathogenesis.
Pursuant to identification of the causative agent as a novel strain of Chlamydia, modification of the disclosed isolation procedures to utilize antibiotics to which
Chlamydia are typically resistant would be advantageous. Utilization of vancomycin, amphotericin B, and members of the aminoglycoside group of antibiotics (gentamicin, neomycin, streptomycin, etc.) in cell culture isolation effectively suppresses contaminating bacterial organisms while permitting Chlamydia growth.
While a substantial body of "evidence" had evolved over the past several years suggesting that the
intracellular organism observed within the intestinal cells in hamster and swine proliferative enteritis cases was a Campylobacter species, heretofore, Chlamydia had never been implicated. In fact, respected researchers in the field had gone so far as to publish journal articles dismissing Chlamydia as a potential causative agent
(McOrist et al., Research in Veterinary Science, 46:27-33 (1989)). This failure to implicate, or even consider,
Chlamydia as an agent is believed to stem, in part, from the atypical behavior exhibited by the novel strain of
Chlamydia described herein.
The two known species of genus Chlamydia, C.
trachomatis and C. psittaci, are known to have an affinity for epithelial cells of mucous membranes, and attachment and penetration appear to involve a heat-labile surface component on the infectious elementary bodies and a trypsin-sensitive receptor on the host cells.
The elementary bodies enter by a phagocytic process, creating a phagosome or inclusion in which the microcolony develops. While the novel Chlamydia of the present
invention does form inclusion bodies in culture, it tends not to be vacuolated in the host. Thus, because this intracellular organism was typically found free in the cytoplasm, it was thought to be a Campylobacter rather than a Chlamydia.
16S rRNA was isolated and sequenced as described in detail in Example 2. Briefly, for 16S RNA sequencing, the novel bacterium was isolated from infected cell culture and media supernate by centrifugation at 800 x g to remove cell debris, followed by isolation of the organism at
12,000 x g. The complete 16S rRNA sequence was determined for the organism using a modified Sanger dideoxy chain termination method, wherein primers complementary to conserved regions were elongated with reverse
transcriptase.
Based on phylogenetic analysis, the novel strain of intracellular bacterium was shown to be related to
Chlamydia, as discussed in Example 2. Based on this analysis, the organism isolated in conjunction with the present invention is believed to be a new strain, and possibly a new species, of Chlamydia.
Effective diagnosis of transmissible proliferative ileitis in hamsters, porcine proliferative enteritis, and other proliferative bowel diseases has been hindered by the time required to culture the causative organism from fecal specimens and by the difficulty in distinguishing the novel organism of the present invention from the various species of Campylobacter which also inhabit the intestines of affected species. As a result of the work presented herein, development of diagnostic tools
promoting rapid and accurate assays for the presence of
this novel strain of Chlamydia, Chlamydia sp. strain SFPD, in biological samples taken from hamsters, swine, ferrets, rabbits, and other species susceptible to proliferative bowel diseases is now possible.
For example, as described in Example 1, polyclonal antibodies, reactive with Chlamydia sp. strain SFPD can be used in diagnostic immunoassys, such as ELISAs, RIAs, to detect the presence of Chlamydia sp. strain SFPD in biological samples which include fecal material and tissue.
Likewise, monoclonal antibodies can be generated using the Chlamydia sp. strain SFPD, isolated by the methods described herein, and standard techniques well known to those skilled in the art. These monoclonal antibodies can be used in diagnostic assays as described above.
Similarly, the isolated Chlamydia sp. strain SFPD can be used as an antigen in an immunoassay, such as the ELISA described in Example 1, to detect antibodies to Chlamydia sp. strain SFPD found in the serum of animals infected with the bacterium.
Isolation of this novel strain of Chlamydia makes possible a determination of the nucleotide sequences of its 16S rRNA molecule, which in turn, makes possible the development of nucleic acid probes to aid in its
detection.
Nucleic acid probes are a sensitive and rapid
alternative to culture methods for the detection of
pathogens, particularly in the case of fastidious or noncultivatable organisms. These probes can be either DNA or RNA. DNA probes, for example, are now in common usage
and can be custom-designed in terms of their sizes and specificities for a variety of prospective applications. The sizes of these probes can range from entire plasmids (kilobases in size) down to simple 10- to 15-base
synthesized oligonucleotides.
DNA probes can be tailored to bind to other DNA, ribosomal RNA (rRNA), or messenger RNA (mRNA). A given probe will bind to specific nucleotide sequences. A radioactive, enzymatic, or organic label bound to the probe allows it to be detected.
DNA probes specific for rRNA sequences have been used successfully in the detection of various pathogens, and various diagnostic kits based on DNA probes are now available for use in clinical labs. The presence of
Chlamydia sp. strain SFPD in biological samples can be detected using these nucleic acid probes. For example, a sample of fecal material from an animal can be hybridized to a DNA probe which is complementary to all, or a
portion, of the 16S rRNA sequence (SEQ. ID. NO: 1)
Five DNA probes (SEQ. ID. NOS: 3, 5, 7, 9 and 11) which hybridize to target sequences of Chlamydia sp.
strain SFPD have been developed as described in detail in Example 3.
Additionally, antibodies reactive with Chlamydia sp. strain SFPD can be used to transfer passive immunity to animals susceptible to the bacterium. These antibodies, either polyclonal or monoclonal, can be formulated for therapeutic use as a pharmaceutical composition comprising appropriate carriers, excipients, and other
pharmaceutically acceptable ingredients, as is known to those skilled in the art of pharmacology. Like other
proteinaceous materials, the antibody preparation is formulated as a sterile, non-pyrogenic composition for parenteral administration. However, any pharmaceutically acceptable route and method of administration of antibody for passive transfer of immunity can be used, such as those described in a standard reference text in this field (e.g., Remington's Pharmaceutical Sciences).
The isolated and purified bacterium Chlamydia sp. strain SFPD can itself be used in a vaccine formulation to be administered to susceptible animals. The Chlamydia sp. strain SFPD can be attenuated so that, although the bacterium remains infectious so that it retains its ability to elicit an immune response in the animal, the attenuated bacterium does not cause significant disease in the host animal. Thus, the administration of the vaccine formulation induces the host animal to produce antibodies reactive against subsequent challenge with Chlamydia sp. strain SFPD, thereby neutralizing the infecting bacterium and preventing significant disease.
Attenuation can be achieved by multiple passaging of the organism and selecting for a weakened strain.
Attenuation can also be achieved by mutation of the bacterium using techniques known to those skilled in the art.
Alternately, the vaccine formulation can be comprised of killed, not just attenuated, Chlamydia sp. strain SFPD. Killing can be achieved by heat treatment or lethal doses of chemicals, such as formalin. In either case, the bacterium comprising the vaccine formulation is capable of eliciting an immune response in the host animal without significant disease.
The vaccine will be formulated for therapeutic use as a pharmaceutical composition comprising appropriate carriers, excipients, and other pharmaceutically
acceptable ingredients, as described above and as known to those skilled in the art of pharmacology. The vaccine formulation may also contain additional materials, such as adjuvants, to increase the immunogenicity of the vaccine. Serum titers of antibodies elicited in response to
immunization with these vaccine formulations can be determined by use of the diagnostic assays described above.
The present invention will now be illustrated by the following examples, which further and more specifically illustrate the invention. EXAMPLE I: Isolation of an intracellular bacterium from hamsters with proliferative ileitis and reproduction of the disease with a pure culture
Isolation procedures
The aseptically removed ilea of three hamsters with experimentally induced proliferative ileitis (21 days post-inoculation of infected ileal homogenate) provided the source material. The ilea were cut into 2.5-cm sections, opened longitudinally, and repeatedly washed with Hank's balanced salt solution (HBSS) without Ca2+ or Mg2+ and 1 mM EDTA (HBSS-EDTA) to remove the intestinal contents. The mucus was removed by incubating the ileal sections in 20% (wt/vol) N-acetyl-cysteine (Sigma Chemical Co., St. Louis, Mo.) for 45 min at 37°C with agitation. The supernatant was decanted, and the sections were washed
twice in HBSS-EDTA and then three times in HBSS. The sections were then transferred to 20 ml of hyaluronidase (1 mg/ml) in HBSS with 5% (wt/vol) bovine serum albumin (BSA) and incubated at 37ºC for 2 hr with agitation to free the epithelial cells. The resulting solutions were successively filtered through a sterilized glass
bead-filled syringe, a 105-μm-pore-size polypropylene mesh, and a 52-μm-pore-size nylon mesh (Spectra/Mesh;
Spectrum Medical Industries, Inc., Los Angeles, Calif.) to remove the larger tissue fragments.
The crude cell suspensions were centrifuged (400 x g for 10 min) and resuspended in HBSS twice. Following a final centrifugation, the cell pellets were resuspended in 50 ml of Leibovitz L-15 media (Sigma) with 10% fetal calf serum, 100 μg of gentamicin sulfate (Sigma) per ml, and 2/5 μg of amphotericin B (Sigma) per ml and incubated overnight at 4°C with agitation.
The cells were separated by centrifugation (400 x g for 10 min) and washed three times in HBSS-EDTA with 5% BSA and resuspended in a minimal volume of HBSS-EDTA with 5% BSA. The cell suspensions were then layered onto preformed (15 min at 15,000 x g and at 4°C) 30% Percoll (Pharmacia LKB Biotechnology, Inc., Piscataway, N.J.) gradients in HBSS-EDTA with 5% BSA and centrifuged at 400 x g for 15 min. The epithelial cell bands (density 1.035 g/ml) were suspended in HBSS with 5% BSA and washed four times in HBSS with 5% BSA followed by centrifugation (400 x g, 10 min).
The cell pellets were resuspended in HBSS with 5% BSA and 0.2% Triton X-100 and incubated at 37ºC for 30 min for agitation to effect cell lysis. The suspensions were then
centrifuged (400 x g, 10 min) to remove cell fragments, and the supernatants were filtered through stacked 20- μm-pore-size nylon (Micron Separations, Inc., Westboro, Mass.) and 0.65-,ym-pore-size nitrocellulose filters
(Whatman Co., Clifton, N.J.). The filtrates were
centrifuged at 10,000 x g for 15 min at 4°C, and the resulting bacterial pellets were washed once in HBSS, recentrifuged, and resuspended in HBSS.
Microbiologic procedures
Three Trypticase soy agar-5% sheep blood plates were inoculated with 250 μl of each bacterial suspension. All plates were incubated at 37ºC. One plate was incubated at ambient atmosphere, one was incubated in an atmosphere consisting of approximately 6% O2, 7% CO2, 7% H2, and 80% N2 obtained as described previously, and the remaining plate was incubated anaerobically. The aerobic and microaerobic plates were examined daily for growth, while the anaerobic plate was examined every 3 days for growth. All plates were held for a minimum of 12 days prior to being
discarded.
Cell culture isolation procedures
All cell lines were obtained from the American Type Culture Collection (Rockville, Md.). Culture media, heat-inactivated fetal calf serum, media supplements, and additives were obtained from Sigma.
Intestine 407 human embryonic intestinal cells (ATCC CCL 6) and GPC-16 guinea pig colonic adenocarcinoma cells (ATCC CCL 242) were grown in Dulbecco's modified Eagle's medium with 4,500 mg of glucose per liter, 110 mg of
sodium pyruvate per liter, 584 mg of L-glutamine per liter, and 10% fetal calf serum (DME). HaK Syrian hamster kidney cells were grown in Eagle's minimum essential media with Hank's salts and 10% fetal calf serum. Vero African green monkey kidney cells were grown in medium 199
containing Hank's salts and 10% fetal calf serum. All cell lines were plated onto 75-cm2 culture flasks (Corning Glass Works, Corning, N.Y.) in the respective media and incubated at 37ºC in a 5% CO2 atmosphere until
approximately 50% confluent. Each cell line was then inoculated with 500 μm. of each isolated bacterial
suspension and incubated at 37°C in a 6% CO2, 6% O2, 88% N2 atmosphere. Cell cultures were split 2:1 by scraping on days 4 and 9 of incubation and examined daily by phase microscopy (Olympus INT; Olympus Corp., Lake Success,
N.Y.) for evidence of bacterial growth. All cell cultures were maintained for a minimum of 14 days before negatives were discarded.
Cell cultures with intracellular bacterial growth were continued in cell culture by scraping and splitting through four doublings. The cell culture supernatant was used to infect additional flasks of the same cell line to expand the culture. Infected cells were frozen at -80°C in the respective media with 10% dimethyl sulfoxide for reference and later use.
Inocula preparation
Four inocula were prepared for the infection studies. The inoculum for the control group (group A) was prepared from two 75-cm2 flasks of confluent uninfected Intestine 407 cells. The cells were mechanically separated from the
flask by scraping, concussion, and vortexing. Triton X-100 was then added to the cell media suspension to a
concentration of 0.2% (vol/vol), and the suspension was incubated at 37°C with agitation for 20 min. The
suspension was then centrifuged (400 x g, 20 min), and the supernatant was filtered through a 20-μm-pore-size nylon filter (Micron Separations, Inc.). The resulting filtrate was centrifuged at 11,000 x g for 20 min at 4°C, and the resulting pellet was resuspended in 10 ml of DME.
The infected inocula were prepared in a similar manner except that a total of six 75-cm2 flasks were processed. Following the filtration through a
20-μm-pore-size nylon filter, the infected inocula were divided into three portions. The group B inoculum was processed identically to the group A control inoculum. The group C inoculum was filtered through a 0.65-μm-pore size cellulose filter (Whatman) prior to final centrifugation, and the group D inoculum was similarly filtered through a 0.2-μm-pore-size cellulose filter (Whatman) prior to final centrifugation. All inocula were held at 4°C after preparation and were utilized within 3 hr of preparation.
Animals
Four adult Syrian hamsters (Hsd;SYR) with 17-day-old litters were purchased from a commercial supplier whose colony had no previous history of proliferative ileitis. The weanling hamsters were separated from their dams, sexed, weighed, ear tagged, and placed into group cages by gender. Post-inoculation, hamsters were housed in
conventional polycarbonate rodent cages and provided a commercial rodent diet (RMH 3000; Agway, Inc., Syracuse,
N.Y.) and water ad libitum. Each hamster was weighed at 3- to 5-day intervals by placing the animal in a clean pretared container.
Animal inoculation
The weanling hamsters were divided into four groups with a conscious attempt to equalize the sex and weight distribution among the groups. Each hamster was given 7.5 mg of cimetidine (Tagamet; SK&F Lab Co., Cidra, Puerto Rico) intraperitoneally 30 min prior to inoculation to induce temporary achlorhydria. Following oral inoculation by gavage, each hamster was given 0.2 mg of dexamethasone (Azium; Schering Corp., Kenilworth, N.J.) intramuscularly.
Control group A hamsters (5 male and 3 female) were inoculated with 1 ml of a cell-free filtrate from
uninfected Intestine 407 cells. Group B hamsters (5 male and 3 female) were inoculated with 1 ml of a cell-free filtrate from infected Intestine 407 cells. Groups C and D hamsters (4 male and 4 female each) were inoculated with 0.65-μm- and 0.2-μm-pore-size filtrates from infected Intestine 407 cells.
Necropsy and tissue processing
Hamsters were killed by an intraperitoneal injection of 25 mg of sodium pentobarbital at day 28
postinoculation. A terminal blood sample of 2 ml was drawn from the right ventricle for serum titer determination by enzyme-linked immunosorbent essay (ELISA), and the ileum was aseptically removed. A small section of the ileum was fixed in McDowell-Trump fixative for light and electron microscopy. The remainder of the ileum was either frozen
(-80°C) for later use or further processed for organism reisolation.
Sections for light microscopy were routinely
processed, embedded in paraffin, cut at 4 μm, and stained with hematoxylin and eosin and with Warthin-Starr silver stains for microscopic evaluation. Light microscopic sections were coded and evaluated without knowledge of experimental group assignment.
Reisolation procedures
Reisolation procedures were identical to those utilized in the initial isolation with the exception that only Intestine 407 cells were inoculated for organism reisolation. The ilea of 3 hamsters from group C
(0.65-μm-pore-size filtrate inoculated) and 2 hamsters from group A (control cell inoculated) were independently processed for reisolation of the organism.
Transmission electron microscopy
Hamster ileal sections fixed in McDowell-Trump fixative were washed twice in 0.122 M Millonig's buffer, immersed in 1.33% osmium tetroxide in 0.122 M Millonig's buffer, dehydrated in graded ethanol solutions, cleared in propylene oxide, and embedded in Epon 812. Alkaline toluidine-blue-stained thick sections were examined for selection of thin sections. Thin sections were mounted on 300-mesh copper grids, stained with lead citrate-uranyl acetate, and examined with a Philips 300 electron
microscope.
Infected Intestine 407 cells (passage 13) for
electron microscopy were removed from the culture flask by
scraping, pelleted by centrifugation (400 x g, 10 min), and fixed in 2.5% glutaraldehyde in Millonig's buffer. The cells were then processed as described above except for the necessity of pelleting the cells by centrifugation between steps.
ELISA technigue
The terminal serum samples, day 28 postinfection, were evaluated for serum titer to the organism by ELISA. A crude whole-cell preparation was used as the antigen in the ELISA procedures. Supernatant from infected Intestine 407 cell cultures (passages 25 to 32) was centrifuged at 400 x g for 10 min to remove large particulates and cells. The supernatant was then centrifuged at 12,000 x g for 15 min at 4°C to pellet the bacteria. The pellet was washed once with phosphate-buffered saline (PBS; 0.01 M, pH 7.4, with 0.02% Na3N), recentrifuged, resuspended in PBS to a density corresponding to a McFarland standard of 2, and refrigerated until used. Campylobacter jejuni (ATCC
29428), isolated from brucella broth, was similarly processed as a control antigen.
Ninety-six-well assay plates (E.I.A. Microtiter
Plates; Flow Laboratories McLean, Va.) were coated with a 1:64 dilution of both the isolated bacterial antigen and C. jejuni at 100 111 per well and dried overnight at 37ºC. Wells were incubated with 100 111 of absolute methanol containing 0.3% H2O2 for 30 min at 37°C to inactivate endogenous peroxidase activity. The plates were then washed twice in ELISA wash buffer (0.15 M NaCl, 0.1 M
Tris-HCl, 0.02% Tween 20 (pH 7.4)) and incubated for 1 hr at room temperature with 200 μl of PBS containing 0.20%
(vol/vol) Tween 20 and 2.5% (wt/vol) nonfat powdered milk per well. Plates were washed twice with ELISA wash, and 100 μl of test sera diluted from 1:100 to 1:12,800 in PBS was applied for 1 hr. at room temperature. After being washed 3 times, plates were incubated for 1 hr. at room temperature with 100 μl of peroxidase-labeled goat
anti-hamster immunoglobulin G (IgG) diluted 1:2,500 in ELISA wash per well. Following an additional 3 washes, bound antibody was detected by the addition of 100 μl of 2,2'-azinobis (3-ethylbenzthiazoline sulfonic acid) substrate (Sigma) for 15 min., and the A405 was determined with an automated ELISA reader (Titertek Multiscan; Flow Laboratories). All assays were performed in duplicate and were repeated if values differed by greater than 10%.
Absorbance values greater than 0.2 absorbance units above that of the control (C. jejuni) were considered positive. Pooled sera from female hamsters from a closed colony without a history of proliferative ileitis were included as a negative control with all tests. Polyclonal antibody production
The bacterial isolate was purified from Intestine 407 cell culture (passage 15 and 16) for antibody production. Culture supernatant was centrifuged at 400 x g for 10 min to remove cell debris, and the resulting supernatant was filtered through a 0.65-μm-pore-size cellulose acetate filter (Whatman). The filtrate was then centrifuged
(12,000 x g for 15 min at 4°C), and the pelleted organisms were washed once in PBS, recentrifuged, and resuspended in 10 ml of PBS containing 4% formalin. Following overnight incubation at 4ºC, the organisms were again isolated by
centrifugation, washed once in Dulbecco's PBS,
recentrifuged, and resuspended in Dulbecco's PBS to a concentration approximating a
McFarland standard of 0.5. The organism suspension was then emulsified with an equal volume of Fruend's complete adjuvant (Sigma Chemical Co.).
Two male rabbits were utilized for antibody
production. Each rabbit was injected with a total of 0.5 ml of the adjuvant-organism mixture divided into 10 sites intradermally on the back. A booster injection of 1.0 ml of the organism in Dulbecco's PBS was given subcutaneously at 40 days postinjection, and sera were collected 7 days later.
The IgG fraction of the rabbit antisera was purified by precipitation with ammonium sulfate (33% final
concentration) followed by ion exchange chromatography. The resulting IgG fractions were then reprecipitated with ammonium sulfate, isolated by centrifugation, and desalted on a Sephadex G25 column (Pharmacia LKB Biotechnology, Inc.) equilibrated and eluted with PBS.
Immunohistochemistry
Fixed ileal sections embedded in paraffin and cut to 4 μm were utilized for immunohistochemistry. Sections were routinely deparaffinized in xylene and rehydrated through decreasingly concentrated ethanol solutions. The sections were then incubated for 1 hr in 0.03% H2O2 in absolute methanol to remove endogenous peroxidase activity.
Following washing in PBS, the sections were incubated for 1 hr in a blocking solution of 0.2% (vol/vol) Tween 20 and 2.5% (wt/vol) nonfat dry milk in PBS. Following an
additional wash, the rabbit anti-organism antibody was applied at a dilution of 1:100 in PBS, and the slides were incubated overnight at 4°C in a humidified chamber. The slides were then washed 4 times in ELISA wash and
incubated for 3 hrs with affinity-purified
peroxidase-labeled goat anti-rabbit IgG (Jackson
Immunoresearch) diluted 1:500 in ELISA wash. The sections were then washed 4 times in ELISA wash, and bound antibody was detected with a commercial peroxidase detection system for immunohistochemistry (HistoMark Black; Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) by following the manufacturer's directions. Controls to ensure
specificity included both infected and uninfected
Intestine 407 cells, preimmunization rabbit sera, and organism-adsorbed immune rabbit antibody.
Results
Isolation and propagation of the organism
Inoculation of cell cultures with two of the
bacterial suspensions resulted in heavy bacterial
contamination and discarding of the cell cultures after 18 hr of incubation. Cell cultures inoculated with the remaining bacterial suspension appeared to be free of bacterial contamination, incubation was continued, and the flasks were split (2:1) on day 4. Intracellular organisms were first observed in both the Intestine 407 and GPC-16 cell lines by phase microscopy on day 8 following
inoculation. Clusters of minute organisms within the cells were readily identified by their rapid motility. The clusters of organisms were extremely variable in size,
from barely discernible within the cell cytoplasm at a 4000 x magnification to large clusters completely filling the distended cells. Occasional cells with small clusters of organisms were observed in mitosis with the cell cluster apparently transferring to one of the daughter cells. No evidence of intracellular bacteria was observed in either the HaK or Vero cell lines.
The organism continued to multiply in the original cell cultures (with additional 2:1 splittings on days 14, 18, and 20) through day 19 postinoculation (Intestine 407) and day 21 postinoculation (GPC-16), when the cultures were contaminated. The organism was readily and
continually (more than 40 passages) propagated by
infecting confluent Intestine 407 cell cultures with the supernatant from infected cultures (1 ml of infected supernatant per 25-cm2 surface area). During the first 5 passages in cell culture, intracellular organisms could be detected by phase microscopy within 72 hr of infection, with the interval between infection and microscopic detection decreasing in later passages. Cell culture monolayer viability decreased from 10 days (passage 1) to 6 days by passage 5. Following the initial 5 passages in cell culture, organisms were detected by phase microscopy at 24 hr post cell culture infection, and monolayer destruction was evident in 4 to 6 days following
infection. No changes in bacterial morphology were evident following up to 40 passages in cell culture. Growth of the organism appeared to be substantially greater on the
Intestine 407 cell line and passage 12 of this line was utilized for inoculum preparation.
Necroosy results
The gastrointestinal tract of all control-inoculated (group A) and 0.2-μm-pore-size filtrate-inoculated (group D) hamsters appeared grossly normal at necropsy. No evidence of epithelial cell proliferation or intracellular bacteria was present on light microscopic examination of hematoxylin- and eosin-stained or Warthin-Starry-stained ileal sections from hamsters in either of these groups.
In 4 (2 male and 2 female) of the 8 group B hamsters (cell-free infected inoculate) and 4 (3 male and 1 female) of the 8 group C hamsters (0.65-μm-pore-size filtrate), the ileum was grossly thickened. Ileal wall thicknesses varied from 2 to 5 mm in these cases. Ileal wall necrosis and abscessation with secondary fibrinopurulent
peritonitis was present in 3 of these hamsters (1 from group B and 2 from group C). Light microscopic examination of ileal sections from hamsters with grossly evident ileal thickening revealed immature and disorganized villus epithelial cells with mitotic figures extending from the crypt region up the entire length of the villus. Numerous small curved bacteria were visible in the apical cytoplasm of the epithelial cells in silver-stained ileal sections of all hamsters with grossly evident ileal thickening. A mixed inflammatory cell infiltrate of neutrophils and macrophages was present in the lamina propria of all hamsters with gross lesions. Mild focal epithelial cell proliferation and intracellular bacteria were present in an additional 2 (1 from group B and 1 from group C) of the 8 hamsters that appeared normal at gross necropsy.
Reisolation results
Three of the 5 bacterial suspensions inoculated into Intestine 407 cell cultures resulted in heavy bacterial contamination at 18 hr of incubation, and these cultures were discarded. The remaining 2 cell cultures (1 group A and 1 group C) remained free of bacterial contamination through day 7 of incubation when intracellular organisms were detected by phase microscopy in the group C
(0.65-μm-pore size filtrate) inoculated cell culture.
Intracellular bacteria were not detected in the group A (control) inoculated cell culture through 14 days of incubation.
Microbiologic results
Of the 8 bacterial suspensions, 3 from the original isolation and 5 from reisolation, only those resulting in contamination of the cell cultures produced any growth on Trypticase soy agar-5% sheep blood plates. Pseudomonas aeruginosa, 1 to 8 colonies per 250 μl, was isolated from all 5 contamination suspensions. No other isolates were detected by any of the incubation conditions.
Transmission electron microscopy results
Numerous intracellular bacteria were observed within the cytoplasm of ileal epithelial cells from hamsters inoculated with the 0.65-μm-pore-size filtrate (group C). The bacteria were free within the epithelial cell
cytoplasm. Macrophages with intracellular bacteria both free in the cytoplasm and in phagosomes were present adjacent to epithelial cells. The bacteria were typically slightly curved on longitudinal sections and measured 1.4
to 1.6 μm in length by 0.25 to 0.38 μm in width. The bacterial cell wall appeared trilaminar and irregular. No flagella were observed.
Examination of infected Intestine 407 cells revealed the presence of bacteria morphologically identical to those seen in the ileal cells of infected hamsters. The bacteria in the Intestine 407 cells measured 1.4 to 1.7 μm in length by 0.26 to 0.34 μm with a similar trilaminar irregular cell wall. A majority of the bacteria in the Intestine 407 cells were free within the cell cytoplasm, although some were membrane bound within vacuoles.
ELISA results
Serum titers of hamsters from group A (control inoculated) ranged from <1:100 to 1:1,600, with a median titer of 1:400. The serum titers from the group D
(0.2-μm-pore size filtrate inoculated) hamsters ranged from <1:100 to 1:800, with a median titer of 1:400. Serum titers of hamsters from group C (0.65-μm-pore size
filtrate inocullted) ranged from 1:1,600 to >1: 12,800, with a median titer of 1:6,400, while the titers of the group B hamsters ranged from 1:1,600 to >1:12,800, with a median of 1:3,200. The serum titers of the group B and group C hamsters were significantly (P < 0.01,
Mann-Whitney test) higher than the titers of either group A or group D hamsters. The highest titers, ranging from 1:6,400 to >1:12,800, were recorded from hamsters with grossly evident ileal thickening at necropsy. The pooled negative control sera consistently titered at <1:100.
Immunohistochemistry results
Organisms labeled with the polyclonal rabbit
anti-organism antibody were present in the ileal sections from all 10 hamsters with histologic evidence of
proliferative ileitis. Organisms were primarily confined to the apical portions of ileal epithelial cells, with few organisms being present in the lamina propria or within the lumen. The distribution of organisms corresponded to the distribution of silver-stained organisms seen on the Warthin-Starry-stained sections from the same hamster. No stained organisms were present within the ileal epithelial cells from any of the 8 group A or 8 group D hamsters.
Organisms specifically labeled with the polyclonal rabbit anti-organism antibody were also present in the infected Intestine 407 cells. No reactivity was present with uninfected Intestine 407 cells, and reactivity was completely eliminated by adsorption of the rabbit antisera with formalin-fixed organisms.
EXAMPLE 2: 16S rRNA seguencing of the intracellular bacterium isolated in Example 1 and its identification as a novel strain of Chlamydia
16S rRNA seouencing
The complete 16S rRNA sequence was determined for the organism isolated in Example 1 using a modified Sanger dideoxy chain termination method wherein primers
complementary to conserved regions were elongated with reverse transcriptase. The complete sequence (SEQ ID NO:1) is shown in Table 1
In the foregoing sequence, A represents the base adenine, C represents the base cytosine, G represents the base guanine, U represents the base uracil, lower-case letters (a, c, g, etc.) are believed to be their upper-case equivalent although this is not known with certainty, n indicates that the identity of the nucleotide is unknown, and (-) represents a gap in the sequence as aligned with the 16S rRNA sequence of E. coli.
Similarity matrix
Based on phylogenetic analysis, the novel strain of intracellular bacterium was related to Chlamydia, as shown in Table 2.
The numbers above the diagonal represent percent similarity. The numbers below the diagonal are percent differences corrected for multiple base changes by the method of Jukes and Cantor (1969).
The relationship among the above species can be summarized as shown in Table 3.
1. Determination of oligonucleotide signatures
Signatures are defined as those segments of the RNA sequence which are unique to any given species or group of phylogenetically-related organisms. Signatures can be found by examination of aligned sequences, noting regions in the desired species or higher phylogenetic group that contain differences at sites conserved in other species. Once such a sequence is found, large numbers of reference sequences are searched (by computer) to verify the
uniqueness of the sequence. The sequence of Chlamydia sp. strain SFPD was compared with over 350 sequences of other bacteria. These signature regions become the target site for DNA probes.
2. Probe Synthesis
Once the desired oligonucleotide signatures are
determined for probe development, DNA that is
complementary to the sequence of the signature can be synthesized using techniques well known to those skilled in the art. For example, an ABI DNA Synthesizer can be used to synthesize the oligonucleotides which serve as probes.
3. Probe Labeling
32PO4-ATP can be used as a substrate by T4
polynucleotide kinase for 5' end-labeling of DNA
oligonucleotides. Briefly, the procedure is as follows. 0.5 ug of oligomer (probe) and 200 uCi radiolabeled ATP are combined and dried under vacuum. The dried pellet is
dissolved in 0.05 ml of kinase buffer containing 11.5 U of Polynucleotide kinase (Pharmacia). This mixture is incubated at 37°C for 30 min. Ammonium acetate and EDTA are then added to stop the reaction. The reaction mixture (0.5 ml) is gravity loaded onto C-8 Bond-Elute columns (Analytichem. Intern.) and is washed 3X with 1 ml of 50 mM ammonium acetate and then once with 1 ml of 5 mM ammonium acetate.
4. Probe specificity to RNA and DNA
Probes can be hybridized with rRNA samples that were used for sequencing reactions. Once these probes have proven to be successful using purified RNA, the probes can be validated using pure cultures of target organisms
(Strain SFPD) and related organisms (e.g., other strains of chlamydia). Probes can target 16S rRNA or 16S rRNA regions of the genome.
The hybridization procedure has been adapted from
Schleicher & Schuell (Keene, N.H.) and is as follows:
Approximately 2-4ug rRNA is denatured in a solution of 6.15 M formaldehyde in 10X SSC (NaCl/Na Citrate buffer) at a temperature of 65°C for 15 min. The denatured rRNA is transferred to a prewashed nitrocellulose (NC) filter in a Slot Blot apparatus (Schleicher and Schuell). This apparatus is a modified dot blot which allows for rapid, high resolution hybridization of nucleic acids. The denatured RNA is baked onto the filter at 80°C for 1h under vacuum. The bake filter is placed in a seal-a-meal plastic bag and hybridization solution containing
formamide, Salmon testis DNA, Denhardts solution, EDTA and SDS is added to the bag. After 20 min incubation at the
hybridization temperature (Th), the solution is removed and replaced with a fresh hybridization solution
containing approximately 1 x 107 cpm of labeled probe. Hybridization of the labeled probe to the rRNA on the filter is carried out at the Th for 18h. After 3 washes at RT with 0.8X SSC (low stringency), the NC is washed 2 times at the Th with 0.8X SSC for 30 min each. Most of the wash is removed, leaving the filter still wet. The filter still in the baggie is read on a Betascope 603 (Betagen, Waltham, MA) which allows for the rapid imaging (i.e., in less than 1 hour) and quantification of
radioactive samples.
Probe Sequences
Probe position: 63
Probe length: 24 -mer
Target sequence: (SEQ ID NO: 2)
Probe sequence: (SEQ ID NO: 3)
CGAACG-----GAACGAUUGCUUCGGUGA Chlamydia sp. strain SFPD ..............G..A....U....C.A. C. trachomatis L2/434 .....G.AGUA-UUAAGAGAGC.U.C.NU Camp. fetus ss fetus
.....A.UGAA-GCU-UC.AGC.U.C.AG Helicobater pylori
.....G.UAACAG-GA.GAAGC.U.C.UC Escherichia coli
...G..GUAACAG-GAGAAAGC.U.C.UU Proteus vuloaris
In the example above, the 16S rRNA sequence of strain SFPD is compared with the sequences of 6 other
microorganisms. Thus, there are 5 base differences between Chlamydia sp. strain SFPD and C. trachomatis and 6
base differences between Chlamydia sp. strain SFPD and C. psittaci.
Probe position: 167
Probe length: 24 -mer
Target sequence: (SEQ ID NO: 4)
Probe sequence: (SEQ ID NO: 5)
CGCUAAUACCGAAUGUGGCGUAGA Chlamydia sp. strain SFPD ........................A.UAU C. trachomatis L2/434
....................U.A.-.U Chlamydia psittaci 6BC
U........U.CC..ACUC.U.-CU Camp, fetus ss fetus
GAU.......A.G..UCUC.U---- Helicobacter pylori
A...........C..AAC.UC---- Escherichia coli
G............C...AC.UC---- Proteus vulgaris
Probe position: 205
Probe length: 24 -mer
Target sequence: (SEQ ID NO: 6)
Probe sequence: (SEQ ID NO: 7)
CUAAAUUACGUUAAAGAAGGGGA-U Chlamydia sp. strain SFPD
.CG.G.A....................... C. trachomatis L2/434
.....A.C.UA...................... Chlamydia psittaci 6BC
-GUU.AGU..GG....U-----.- Camp, fetus ss fetus
------—G.GG.....-----.- Helicobacter pylori
--------GACC....G......C Escherichia coli
-------- GACC....C....U... Proteus vulgaris
Probe position: 455
Probe length: 24 -mer
Target sequence: (SEQ ID NO: 8)
Probe sequence: (SEQ ID NO: 9) GAAGACGGUUAAUACCCGUUGGAU Chlamydia so. strain SFPD
....G.............C..... C. trachomatis L2/434
..GAUU..C....U...AA.C... Chlamydia psittaci 6BC
----------------------C Camp, fetus ss fetus
------------------------ Helicobacter pylori
..GU.AA.........UU.GCUCA Escherichia coli
UG.U.AA........U.U.GUC.A Proteus vulgaris
Probe position: 591
Probe length: 24 -mer
Target sequence: (SEQ ID NO: 10)
Probe sequence: (SEQ ID NO: 11)
AGGUAAGUUAGUUGUCAAAUCUCG Chlamydia sp. strain SFPD ....................GA.... C. trachomatis L2/434
...A.......A....U.......U.. Chlamydia psittaci 6BC
UAUC....CUU...G. ....A.A Camp, fetus ss fetus
UA..C...C..G...G.....C.UA Helicobacter pylori
U.U....C...A...G.....C. C Escherichia coli
-AU....C...A...G...G.C.C Proteus vulgaris
Eguivalents
Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.
Claims
1. A substantially pure culture of Chlamydia sp. strain SFPD.
2. The substantially pure culture of Claim 1 comprising Chlamydia sp. strain SFPD accorded ATCC Accession
NO.M83313.
3. A substantially pure culture of one or more of
Chlamydia accorded ATCC Accession No. M83313, taxonomic equivalents thereof, and mutants or variants thereof.
4. The purified and isolated organism of Claim 3
Chlamydia sp. strain SFPD.
5. The purified and isolated organism of Claim 4
containing a 16S ribosomal RNA sequence encompassed by SEQ ID NO:l.
6. A method for isolating Chlamydia sp. strain SFPD from the intestinal epithelial cells of an animal which comprises isolating said epithelial cells by
hyaluronidase digestion.
7. The method as described in claim 6 wherein said
animal is a hamster, pig, rabbit or ferret.
8. A method for isolating Chlamydia sp. strain SFPD
which comprises propagating the organism in a
reduced-oxygen environment.
9. A method for isolating Chlamydia sp. strain SFPD which comprises propagating the Chlamydia sp. strain SFPD on Intestine 407 human embryonic intestinal cells or GPC-16 guinea pig colonic adenocarcinoma cells.
10. A method for reproducing transmissible proliferative ileitis in animals which comprises inoculating an animal with the substantially pure culture of Claim 1.
11. A method for generating polyclonal antibodies
reactive with Chlamydia sp. strain SFPD which comprises injecting a host animal with the Chlamydia sp. strain SFPD or cellular components thereof.
12. A polyclonal antibody reactive with Chlamydia sp.
strain SFDP produced by the method of Claim 11.
13. A method for generating monoclonal antibodies
reactive with Chlamydia sp. strain SFPD which comprises injecting a host animal with Chlamydia sp. strain SFPD or cellular components thereof.
14. A monoclonal antibody reactive with Chlamydia sp.
strain SFPD produced by the method of Claim 13.
15. A method for detecting Chlamydia sp. strain SFPD in a biological material sample from an animal,
comprising:
a) obtaining a biological sample from an animal; b) contacting the sample with an antibody reactive with Chlamydia sp. strain SFPD under conditions whereby the antibody reacts with the Chlamydia sp. strain SFPD and
c) detecting antibody-bound sample wherein antibody bound to the sample is an indication of the presence of Chlamydia sp. strain SFPD.
16. The method of Claim 15 wherein the biological sample is tissue or fecal material.
17. The method of Claim 15 wherein the antibodies are
labeled with a label selected from the group
consisting fluorescein, rhodamine, and peroxidase.
18. The method of Claim 15 wherein the biological
material sample is derived from hamsters, swine, rabbits, or ferrets.
19. The method of Claim 15 wherein the antibodies are
polyclonal antibodies produced by the method of Claim 11.
20. The method of Claim 15 wherein the antibodies are
monoclonal antibodies produced by the method of Claim 13.
21. A method for diagnosing transmissible proliferative ileitis in an animal by detecting antibody reactive with Chlamydia sp. strain SFPD present in the serum of an animal, comprising:
a) obtaining a serum sample from the animal;
b) contacting the serum sample with purified and isolated Chlamydia sp. strain SFPD under
conditions whereby the antibody present in the serum sample reacts with the Chlamydia sp. SFPD; and
c) detecting serum antibody bound to the Chlamydia sp. strain SFPD wherein antibody bound to the organism is an indication of transmissible proliferative ileitis.
22. The method of Claim 21 wherein the purified and
isolated Chlamydia sp. strain SFPD is isolated according to the methods of Claims 6, 8 or 9.
23. A nucleic acid probe for the detection of Chlamydia sp. strain SFPD comprising a nucleic acid which hybridizes to all or a part of the sequence
represented by SEQ ID NO:1.
24. The nucleic acid probe of Claim 23 wherein the
nucleic acid is DNA.
25. The nucleic acid probe of Claim 23 as represented by SEQ ID NO: 3.
26. The nucleic acid probe of Claim 23 as represented by SEQ ID NO: 5.
27. The nucleic acid probe of Claim 23 as represented by SEQ ID NO: 7.
28. The nucleic acid probe of Claim 23 as represented by SEQ ID NO: 9.
29. The nucleic acid probe of Claim 23 as represented by SEQ ID NO: 11.
30. A method of detecting Chlamydia sp. strain SFPD
present in a biological sample in an animal,
comprising:
a) obtaining a biological sample from an animal; b) treating the sample in a manner that renders 16S ribosomal RNA present in the sample available for hybridization with a complementary nucleic acid sequence thereby producing a treated sample;
c) contacting the treated sample with at least one probe which is a nucleic acid sequence which hybridizes with all or a portion of a nucleic acid sequence represented by SEQ ID NO:1; and d) detecting the hybridization of 16S ribosomal RNA from the sample with the nucleic acid probe, wherein hybridization is an indication of the presence of Chlamydia sp. strain SFPD.
31. A method of detecting Chlamydia sp. strain SFPD present in a biological sample in an animal,
comprising:
a) obtaining a biological sample from an animal; b) treating the sample in a manner that renders 16S ribosomal RNA regions of the genome present in the sample available for hybridization with a complementary nucleic acid sequence thereby producing a treated sample;
c) contacting the treated sample with at least one probe which is a nucleic acid sequence which hybridizes with all or a portion of a nucleic acid sequence represented by SEQ ID NO:1; and d) detecting the hybridization of 16S ribosomal RNA regions of the genome from the sample with the nucleic acid probe, wherein hybridization is an indication of the presence of Chlamydia sp.
strain SFPD.
32. The method of Claim 30 wherein the nucleic acid probe is selected from the group consisting of: SEQ ID NO.:
3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11.
33. The method of Claim 30 or 31 wherein the biological sample is tissue or fecal material.
34. A method of passively transferring immunity against Chlamydia sp. strain SFPD to an animal comprising administering to the animal an antibody reactive with Chlamydia sp. strain SFPD.
35. The method of Claim 33 wherein the antibody is a polyclonal antibody produced by the method of Claim 11.
36. The method of Claim 33 wherein the antibody is a
monoclonal antibody produced by the method of Claim 13.
37. A vaccine formulation comprising an attenuated
Chlamydia sp. strain SFPD in which the Chlamydia sp. strain SFPD is infectious without causing significant disease in the animal host to be vaccinated.
38. A vaccine formulation comprising killed Chlamydia sp.
strain SFPD in which the killed Chlamydia sp. strain SFPD is infectious without causing significant disease in the animal host to be vaccinated.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US748,998 | 1976-12-09 | ||
US74899891A | 1991-08-23 | 1991-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993004163A1 true WO1993004163A1 (en) | 1993-03-04 |
Family
ID=25011801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/007103 WO1993004163A1 (en) | 1991-08-23 | 1992-08-24 | Strain of chlamydia |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1993004163A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19860438C1 (en) * | 1998-12-28 | 2000-09-07 | Sonntag Hans Guenther | Process for the production of auto vaccines for the treatment of chlamydiosis in mammals and humans |
US6261769B1 (en) * | 1998-03-31 | 2001-07-17 | The United States Of America As Represented By The Secretary Of Agriculture | Intergenic spacer target sequence for detecting and distinguishing Chlamydial species or strains |
US6921536B2 (en) | 2000-12-20 | 2005-07-26 | Akzo Nobel N.V. | Lawsonia intracellularis vaccine |
EP1589114A2 (en) * | 1994-10-14 | 2005-10-26 | Gen-Probe Incorporated | Compositions and methods for the detection of chlamydia trachomatis |
-
1992
- 1992-08-24 WO PCT/US1992/007103 patent/WO1993004163A1/en active Search and Examination
Non-Patent Citations (4)
Title |
---|
BIOLOGICAL ABSTRACTS vol. 42 , 1991, Philadelphia, PA, US; abstract no. 17820, FOX J G ET AL. 'LOCALIZATION OF CHLAMYDIA-SP STRAIN SFPD IN CLO ASSOCIATED PROLIFERATIVE INTESTINAL TISSUE OF ANIMALS BY FA MONOCLONAL ANTIBODY AND IN-SITU DNA HYBRIDIZATION' * |
BIOLOGICAL ABSTRACTS vol. 42 , 1991, Philadelphia, PA, US; abstract no. 17821, STILLS H ET AL. 'ANEW CHLAYDIA-SP STRAIN SFPD ISOLATED FROM TRANSMISSIBLE PROLIFERATIVE ILEITIS IN HAMSTERS' * |
BIOLOGICAL ABSTRACTS vol. 67, no. 7 , 1979, Philadelphia, PA, US; abstract no. 42121, RONSHOLT T I 'INFECTION IN DANISH CATTLE' page 4181 ; * |
INNERE MEDIZIN vol. 14, no. 2, March 1987, pages 45 - 48 W. BORNSCHEIN ET AL. 'CHLAMYDIA-TRACHOMATIS-NACHWEIS BEI ENTZÜNDLICHEN UND ULZERöSEN ERKRANKUNGEN DES DUODENUMS UND ILEUMS' * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1589114A2 (en) * | 1994-10-14 | 2005-10-26 | Gen-Probe Incorporated | Compositions and methods for the detection of chlamydia trachomatis |
EP1589114A3 (en) * | 1994-10-14 | 2008-03-12 | Gen-Probe Incorporated | Compositions and methods for the detection of chlamydia trachomatis |
US6261769B1 (en) * | 1998-03-31 | 2001-07-17 | The United States Of America As Represented By The Secretary Of Agriculture | Intergenic spacer target sequence for detecting and distinguishing Chlamydial species or strains |
DE19860438C1 (en) * | 1998-12-28 | 2000-09-07 | Sonntag Hans Guenther | Process for the production of auto vaccines for the treatment of chlamydiosis in mammals and humans |
US6921536B2 (en) | 2000-12-20 | 2005-07-26 | Akzo Nobel N.V. | Lawsonia intracellularis vaccine |
US7491401B2 (en) | 2000-12-20 | 2009-02-17 | Intervet International B.V. | Lawsonia intracellularis vaccine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1403643B2 (en) | Lawsonia intracellularis cultivation, anti-lawsonia intracelluaris vaccines and diagnostic agents | |
Russell et al. | Experimental Campylobacter jejuni infection in Macaca nemestrina | |
El‐Houadfi et al. | The isolation and characterisation of six avian infectious bronchitis viruses isolated in Morocco | |
Stills Jr | Isolation of an intracellular bacterium from hamsters (Mesocricetus auratus) with proliferative ileitis and reproduction of the disease with a pure culture | |
Fouz et al. | Isolation of a new serovar of Vibrio vulnificus pathogenic for eels cultured in freshwater farms | |
Guner et al. | A novel, fast-growing Borrelia sp. isolated from the hard tick Hyalomma aegyptium in Turkey | |
Enroth et al. | One stomach-one strain (Does Helicobacter pylori strain variation influence disease outcome?) | |
Hampson et al. | A Review-Intestinal spirochaetal infections of pigs: An overview with an Australian perspective | |
US5693776A (en) | Nucleic acids specific for Rochalimaea quintana | |
WO1998040099A9 (en) | Leptospira pathogens | |
EP0759988B1 (en) | NUCLEIC ACIDS OF $i(ROCHALIMAEA HENSELAE) AND $i(ROCHALIMAEA QUINTANA) AND METHODS AND COMPOSITIONS FOR DIAGNOSING $i(ROCHALIMAEA HENSELAE) AND $i(ROCHALIMAEA QUINTANA) INFECTION | |
WO1993004163A1 (en) | Strain of chlamydia | |
Muñoz et al. | A Brucella melitensis H38Δ wbkF rough mutant protects against Brucella ovis in rams | |
JP3394047B2 (en) | Methods for producing enhanced antigenic enterobacteria and vaccines containing the same | |
JP2000500027A (en) | Detection, prevention and treatment of papillomatus digital dermatitis | |
Forester et al. | Isolation of Helicobacter mustelae it from ferrets in New Zealand | |
AU6083798A (en) | Leptospira pathogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |